<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37725085</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2023</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>Evolution of a functionally intact but antigenically distinct DENV fusion loop.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">RP87555</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.87555</ELocationID><Abstract><AbstractText>A hallmark of dengue virus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which is associated with deadly DENV secondary infection, complicates the identification of correlates of protection, and negatively impacts the safety and efficacy of DENV vaccines. Antibody-dependent enhancement is linked to antibodies targeting the fusion loop (FL) motif of the envelope protein, which is completely conserved in mosquito-borne flaviviruses and required for viral entry and fusion. In the current study, we utilized saturation mutagenesis and directed evolution to engineer a functional variant with a mutated FL (D2-FL), which is not neutralized by FL-targeting monoclonal antibodies. The FL mutations were combined with our previously evolved prM cleavage site to create a mature version of D2-FL (D2-FLM), which evades both prM- and FL-Abs but retains sensitivity to other type-specific and quaternary cross-reactive (CR) Abs. CR serum from heterotypic (DENV4)-infected non-human primates (NHP) showed lower neutralization titers against D2-FL and D2-FLM than isogenic wildtype DENV2 while similar neutralization titers were observed in serum from homotypic (DENV2)-infected NHP. We propose D2-FL and D2-FLM as valuable tools to delineate CR Ab subtypes in serum as well as an exciting platform for safer live-attenuated DENV vaccines suitable for na&#xef;ve individuals and children.</AbstractText><CopyrightInformation>&#xa9; 2023, Meganck et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meganck</LastName><ForeName>Rita M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Saint Louis University, Saint Louis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Deanna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snoderly-Foster</LastName><ForeName>Lisa J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Saint Louis University, Saint Louis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalben</LastName><ForeName>Yago R</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Saint Louis University, Saint Louis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiono</LastName><ForeName>Devina</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8330-0396</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeSilva</LastName><ForeName>Arivianda M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-3317-5950</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baric</LastName><ForeName>Ralph S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Longping V</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0001-7582-8396</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Saint Louis University, Saint Louis, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AI107731</GrantID><Agency>National Institute of Allergy and Infectious Diseases</Agency><Country/></Grant><Grant><GrantID>P01AI106695</GrantID><Agency>National Institute of Allergy and Infectious Diseases</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>doi: 10.1101/2023.03.22.533803</RefSource></CommentsCorrections><CommentsCorrections RefType="UpdateOf"><RefSource>doi: 10.7554/eLife.87555.1</RefSource></CommentsCorrections><CommentsCorrections RefType="UpdateOf"><RefSource>doi: 10.7554/eLife.87555.2</RefSource></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">evolution</Keyword><Keyword MajorTopicYN="N">fusion loop</Keyword><Keyword MajorTopicYN="N">infectious disease</Keyword><Keyword MajorTopicYN="N">microbiology</Keyword><Keyword MajorTopicYN="N">saturation mutagenesis</Keyword><Keyword MajorTopicYN="N">serum</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">viruses</Keyword></KeywordList><CoiStatement>RM inventor on a patent application (#63/320,922) filed on the subject matter of the manuscript, DZ, SD, LS, YD, DT, LW, AD No competing interests declared, RB member of the advisory board of VaxArt and Invivyd and has collaborations with Takeda, Pfizer, Moderna, Ridgeback Biosciences, Gilead, and Eli Lily. Inventor on a patent application (#63/320,922) filed on the subject matter of the manuscript, LT Inventor on a patent application (#63/320,922) filed on the subject matter of the manuscript</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>19</Day><Hour>17</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>19</Day><Hour>17</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>19</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37725085</ArticleId><ArticleId IdType="doi">10.7554/eLife.87555</ArticleId><ArticleId IdType="pii">87555</ArticleId><ArticleId IdType="pmc">PMC10508882</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrade DV, Warnes C, Young E, Katzelnick LC, Balmaseda A, de Silva AM, Baric RS, Harris E. Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. Scientific Reports. 2019;9:16258. doi: 10.1038/s41598-019-52511-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-52511-z</ArticleId><ArticleId IdType="pmc">PMC6838341</ArticleId><ArticleId IdType="pubmed">31700029</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelin M, Sj&#xf6;lin J, Kahn F, Ljunghill Hedberg A, Rosdahl A, Skorup P, Werner S, Woxenius S, Askling HH. Qdenga - A promising dengue fever vaccine; can it be recommended to non-immune travelers? Travel Medicine and Infectious Disease. 2023;54:102598. doi: 10.1016/j.tmaid.2023.102598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2023.102598</ArticleId><ArticleId IdType="pubmed">37271201</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous Dengue vaccine: WHO position paper, September 2018 &#x2013; Recommendations. Vaccine. 2019;37:4848&#x2013;4849. doi: 10.1016/j.vaccine.2018.09.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.063</ArticleId><ArticleId IdType="pubmed">30424888</ArticleId></ArticleIdList></Reference><Reference><Citation>Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney M-C, Medits I, Sharma A, Simon-Lori&#xe8;re E, Sakuntabhai A, Cao-Lormeau V-M, Haouz A, England P, Stiasny K, Mongkolsapaya J, Heinz FX, Screaton GR, Rey FA. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536:48&#x2013;53. doi: 10.1038/nature18938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18938</ArticleId><ArticleId IdType="pubmed">27338953</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NTH, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host &amp; Microbe. 2010;8:271&#x2013;283. doi: 10.1016/j.chom.2010.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GRW, Simmons CP, Scott TW, Farrar JJ, Hay SI. The global distribution and burden of dengue. Nature. 2013;496:504&#x2013;507. doi: 10.1038/nature12060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI, Reithinger R. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLOS Neglected Tropical Diseases. 2012;6:e1760. doi: 10.1371/journal.pntd.0001760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001760</ArticleId><ArticleId IdType="pmc">PMC3413714</ArticleId><ArticleId IdType="pubmed">22880140</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers MT, Schwarz MC, Sourisseau M, Gray ES, Evans MJ. Probing zika virus neutralization determinants with glycoprotein mutants bearing linear epitope insertions. Journal of Virology. 2018;92:e00505-18. doi: 10.1128/JVI.00505-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00505-18</ArticleId><ArticleId IdType="pmc">PMC6146680</ArticleId><ArticleId IdType="pubmed">29976678</ArticleId></ArticleIdList></Reference><Reference><Citation>Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang S-T, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. Journal of Virology. 2013;87:52&#x2013;66. doi: 10.1128/JVI.02273-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02273-12</ArticleId><ArticleId IdType="pmc">PMC3536401</ArticleId><ArticleId IdType="pubmed">23077306</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLOS Pathogens. 2014;10:e1004386. doi: 10.1371/journal.ppat.1004386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004386</ArticleId><ArticleId IdType="pmc">PMC4183589</ArticleId><ArticleId IdType="pubmed">25275316</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745&#x2013;748. doi: 10.1126/science.1185181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1185181</ArticleId><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NTH, Duangchinda T, Grimes JM, Tsai W-Y, Lai C-Y, Wang W-K, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nature Immunology. 2015;16:170&#x2013;177. doi: 10.1038/ni.3058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3058</ArticleId><ArticleId IdType="pmc">PMC4445969</ArticleId><ArticleId IdType="pubmed">25501631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebi KL, Nealon J. Dengue in a changing climate. Environmental Research. 2016;151:115&#x2013;123. doi: 10.1016/j.envres.2016.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2016.07.026</ArticleId><ArticleId IdType="pubmed">27475051</ArticleId></ArticleIdList></Reference><Reference><Citation>Elong Ngono A, Shresta S. Cross-reactive t cell immunity to dengue and zika viruses: new insights into vaccine development. Frontiers in Immunology. 2019;10:1316. doi: 10.3389/fimmu.2019.01316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01316</ArticleId><ArticleId IdType="pmc">PMC6579874</ArticleId><ArticleId IdType="pubmed">31244855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, Jr, de Silva AM, Baric RS. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio. 2015;6:e01461-15. doi: 10.1128/mBio.01461-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01461-15</ArticleId><ArticleId IdType="pmc">PMC4620467</ArticleId><ArticleId IdType="pubmed">26463165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallichotte EN, Baric TJ, Nivarthi U, Delacruz MJ, Graham R, Widman DG, Yount BL, Durbin AP, Whitehead SS, de Silva AM, Baric RS. Genetic variation between dengue virus type 4 strains impacts human antibody binding and neutralization. Cell Reports. 2018;25:1214&#x2013;1224. doi: 10.1016/j.celrep.2018.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.10.006</ArticleId><ArticleId IdType="pmc">PMC6226424</ArticleId><ArticleId IdType="pubmed">30380413</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Purcell RH, Lai CJ. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. Journal of Virology. 2004;78:12919&#x2013;12928. doi: 10.1128/JVI.78.23.12919-12928.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.23.12919-12928.2004</ArticleId><ArticleId IdType="pmc">PMC525008</ArticleId><ArticleId IdType="pubmed">15542644</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski GD, Firestone CY, Whitehead SS. Genetic determinants of japanese encephalitis virus vaccine strain SA14-14-2 that govern attenuation of virulence in mice. Journal of Virology. 2015;89:6328&#x2013;6337. doi: 10.1128/JVI.00219-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00219-15</ArticleId><ArticleId IdType="pmc">PMC4474313</ArticleId><ArticleId IdType="pubmed">25855730</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239:476&#x2013;481. doi: 10.1126/science.3277268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3277268</ArticleId><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, Marchette NJ. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. The American Journal of Tropical Medicine and Hygiene. 2003;69:5&#x2013;11. doi: 10.4269/ajtmh.2003.69.6_suppl.0690005.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2003.69.6_suppl.0690005</ArticleId><ArticleId IdType="pubmed">14740949</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly AM, Alturki SO, Alturki SO, Connors J, Haddad EK. Challenges in dengue vaccines development: pre-existing infections and cross-reactivity. Frontiers in Immunology. 2020;11:1055. doi: 10.3389/fimmu.2020.01055.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01055</ArticleId><ArticleId IdType="pmc">PMC7325873</ArticleId><ArticleId IdType="pubmed">32655548</ArticleId></ArticleIdList></Reference><Reference><Citation>Juraska M, Magaret CA, Shao J, Carpp LN, Fiore-Gartland AJ, Benkeser D, Girerd-Chambaz Y, Langevin E, Frago C, Guy B, Jackson N, Duong Thi Hue K, Simmons CP, Edlefsen PT, Gilbert PB. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. PNAS. 2018;115:E8378&#x2013;E8387. doi: 10.1073/pnas.1714250115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1714250115</ArticleId><ArticleId IdType="pmc">PMC6130398</ArticleId><ArticleId IdType="pubmed">30127007</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358:929&#x2013;932. doi: 10.1126/science.aan6836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan6836</ArticleId><ArticleId IdType="pmc">PMC5858873</ArticleId><ArticleId IdType="pubmed">29097492</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein DE, Choi JL, Harrison SC. Structure of a dengue virus envelope protein late-stage fusion intermediate. Journal of Virology. 2013;87:2287&#x2013;2293. doi: 10.1128/JVI.02957-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02957-12</ArticleId><ArticleId IdType="pmc">PMC3571469</ArticleId><ArticleId IdType="pubmed">23236058</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotaki T, Kurosu T, Grinyo-Escuer A, Davidson E, Churrotin S, Okabayashi T, Puiprom O, Mulyatno KC, Sucipto TH, Doranz BJ, Ono K-I, Soegijanto S, Kameoka M. An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency. Scientific Reports. 2021;11:12987. doi: 10.1038/s41598-021-92403-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-92403-9</ArticleId><ArticleId IdType="pmc">PMC8217507</ArticleId><ArticleId IdType="pubmed">34155267</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudlacek ST, Metz S, Thiono D, Payne AM, Phan TTN, Tian S, Forsberg LJ, Maguire J, Seim I, Zhang S, Tripathy A, Harrison J, Nicely NI, Soman S, McCracken MK, Gromowski GD, Jarman RG, Premkumar L, de Silva AM, Kuhlman B. Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies. Science Advances. 2021;7:eabg4084. doi: 10.1126/sciadv.abg4084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abg4084</ArticleId><ArticleId IdType="pmc">PMC8519570</ArticleId><ArticleId IdType="pubmed">34652943</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C-Y, Tsai W-Y, Lin S-R, Kao C-L, Hu H-P, King C-C, Wu H-C, Chang G-J, Wang W-K. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. Journal of Virology. 2008;82:6631&#x2013;6643. doi: 10.1128/JVI.00316-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00316-08</ArticleId><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C-Y, Williams KL, Wu Y-C, Knight S, Balmaseda A, Harris E, Wang W-K. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLOS Neglected Tropical Diseases. 2013;7:e2451. doi: 10.1371/journal.pntd.0002451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002451</ArticleId><ArticleId IdType="pmc">PMC3777924</ArticleId><ArticleId IdType="pubmed">24069496</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez AL, Adams C, Ylade M, Jadi R, Daag JV, Molloy CT, Agrupis KA, Kim DR, Silva MW, Yoon I-K, White L, Deen J, de Silva AM. Determining dengue virus serostatus by indirect IgG ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a prospective population-based study. The Lancet Global Health. 2021;9:e44&#x2013;e51. doi: 10.1016/S2214-109X(20)30392-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30392-2</ArticleId><ArticleId IdType="pmc">PMC9358663</ArticleId><ArticleId IdType="pubmed">33212030</ArticleId></ArticleIdList></Reference><Reference><Citation>Meganck RM. Saturation-Mutagenesis-pipeline. swh:1:rev:def6f74d7c9bec9e52835e4c0fd028bcf3aaf0afSoftware Heritage. 2022 https://archive.softwareheritage.org/swh:1:dir:05d061a035a79dc2b0abbc336c8b48ecbc248a32;origin=https://github.com/TseLabVirology/Saturation-Mutagenesis-Pipeline;visit=swh:1:snp:a277869bd1e1c18119eb5e67c1b829f1a6f2c65c;anchor=swh:1:rev:def6f74d7c9bec9e52835e4c0fd028bcf3aaf0af</Citation></Reference><Reference><Citation>Messer WB, Yount B, Hacker KE, Donaldson EF, Huynh JP, de Silva AM, Baric RS. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLOS Neglected Tropical Diseases. 2012;6:e1486. doi: 10.1371/journal.pntd.0001486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001486</ArticleId><ArticleId IdType="pmc">PMC3289595</ArticleId><ArticleId IdType="pubmed">22389731</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, Pigott DM, Shearer FM, Johnson K, Earl L, Marczak LB, Shirude S, Davis Weaver N, Gilbert M, Velayudhan R, Jones P, Jaenisch T, Scott TW, Reiner RC, Jr, Hay SI. The current and future global distribution and population at risk of dengue. Nature Microbiology. 2019;4:1508&#x2013;1515. doi: 10.1038/s41564-019-0476-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-019-0476-8</ArticleId><ArticleId IdType="pmc">PMC6784886</ArticleId><ArticleId IdType="pubmed">31182801</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz SW, Gallichotte EN, Brackbill A, Premkumar L, Miley MJ, Baric R, de Silva AM. In vitro assembly and stabilization of dengue and zika virus envelope protein homo-dimers. Scientific Reports. 2017;7:4524. doi: 10.1038/s41598-017-04767-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04767-6</ArticleId><ArticleId IdType="pmc">PMC5495877</ArticleId><ArticleId IdType="pubmed">28674411</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427:313&#x2013;319. doi: 10.1038/nature02165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02165</ArticleId><ArticleId IdType="pubmed">14737159</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi B-E, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. Journal of Virology. 2006;80:12149&#x2013;12159. doi: 10.1128/JVI.01732-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01732-06</ArticleId><ArticleId IdType="pmc">PMC1676294</ArticleId><ArticleId IdType="pubmed">17035317</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabaa MA, Girerd-Chambaz Y, Duong Thi Hue K, Vu Tuan T, Wills B, Bonaparte M, van der Vliet D, Langevin E, Cortes M, Zambrano B, Dunod C, Wartel-Tram A, Jackson N, Simmons CP. Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy. eLife. 2017;6:e24196. doi: 10.7554/eLife.24196.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.24196</ArticleId><ArticleId IdType="pmc">PMC5584992</ArticleId><ArticleId IdType="pubmed">28871961</ArticleId></ArticleIdList></Reference><Reference><Citation>Raut R, Corbett KS, Tennekoon RN, Premawansa S, Wijewickrama A, Premawansa G, Mieczkowski P, R&#xfc;ckert C, Ebel GD, De Silva AD, de Silva AM. Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies. PNAS. 2019;116:227&#x2013;232. doi: 10.1073/pnas.1812055115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1812055115</ArticleId><ArticleId IdType="pmc">PMC6320508</ArticleId><ArticleId IdType="pubmed">30518559</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey FA, Stiasny K, Vaney M-C, Dellarole M, Heinz FX. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Reports. 2018;19:206&#x2013;224. doi: 10.15252/embr.201745302.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201745302</ArticleId><ArticleId IdType="pmc">PMC5797954</ArticleId><ArticleId IdType="pubmed">29282215</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockstroh A, Barzon L, Pacenti M, Pal&#xf9; G, Niedrig M, Ulbert S. Recombinant envelope-proteins with mutations in the conserved fusion loop allow specific serological diagnosis of dengue-infections. PLOS Neglected Tropical Diseases. 2015;9:e0004218. doi: 10.1371/journal.pntd.0004218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0004218</ArticleId><ArticleId IdType="pmc">PMC4643925</ArticleId><ArticleId IdType="pubmed">26565964</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei H-Y, Wilschut J, Smit JM. Immature dengue virus: A veiled pathogen? PLOS Pathogens. 2010;6:e1000718. doi: 10.1371/journal.ppat.1000718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000718</ArticleId><ArticleId IdType="pmc">PMC2798752</ArticleId><ArticleId IdType="pubmed">20062797</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinski A, Dejnirattisai W, Guardado-Calvo P, Vaney M-C, Sharma A, Duquerroy S, Supasa P, Wongwiwat W, Haouz A, Barba-Spaeth G, Mongkolsapaya J, Rey FA, Screaton GR. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nature Communications. 2017;8:15411. doi: 10.1038/ncomms15411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15411</ArticleId><ArticleId IdType="pmc">PMC5457521</ArticleId><ArticleId IdType="pubmed">28534525</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Zhang X, Dejnirattisai W, Dai X, Gong D, Wongwiwat W, Duquerroy S, Rouvinski A, Vaney M-C, Guardado-Calvo P, Haouz A, England P, Sun R, Zhou ZH, Mongkolsapaya J, Screaton GR, Rey FA. The epitope arrangement on flavivirus particles contributes to Mab C10&#x2019;s extraordinary neutralization breadth across Zika and dengue viruses. Cell. 2021;184:6052&#x2013;6066. doi: 10.1016/j.cell.2021.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.11.010</ArticleId><ArticleId IdType="pmc">PMC8724787</ArticleId><ArticleId IdType="pubmed">34852239</ArticleId></ArticleIdList></Reference><Reference><Citation>Slon-Campos JL, Dejnirattisai W, Jagger BW, L&#xf3;pez-Camacho C, Wongwiwat W, Durnell LA, Winkler ES, Chen RE, Reyes-Sandoval A, Rey FA, Diamond MS, Mongkolsapaya J, Screaton GR. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nature Immunology. 2019;20:1291&#x2013;1298. doi: 10.1038/s41590-019-0477-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0477-z</ArticleId><ArticleId IdType="pmc">PMC6839414</ArticleId><ArticleId IdType="pubmed">31477918</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE., Jr Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. Journal of Virology. 2012;86:2665&#x2013;2675. doi: 10.1128/JVI.06335-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06335-11</ArticleId><ArticleId IdType="pmc">PMC3302281</ArticleId><ArticleId IdType="pubmed">22171265</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE., Jr The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio. 2013;4:e00873-13. doi: 10.1128/mBio.00873-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00873-13</ArticleId><ArticleId IdType="pmc">PMC3870244</ArticleId><ArticleId IdType="pubmed">24255124</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Grifoni A, Sette A, Weiskopf D. Human T cell response to dengue virus infection. Frontiers in Immunology. 2019;10:2125. doi: 10.3389/fimmu.2019.02125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02125</ArticleId><ArticleId IdType="pmc">PMC6737489</ArticleId><ArticleId IdType="pubmed">31552052</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse LV, Klinc KA, Madigan VJ, Castellanos Rivera RM, Wells LF, Havlik LP, Smith JK, Agbandje-McKenna M, Asokan A. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. PNAS. 2017;114:E4812&#x2013;E4821. doi: 10.1073/pnas.1704766114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1704766114</ArticleId><ArticleId IdType="pmc">PMC5474820</ArticleId><ArticleId IdType="pubmed">28559317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse LV, Meganck RM, Dong S, Adams LE, White LJ, Mallory ML, Jadi R, de Silva AM, Baric RS. Generation of Mature DENVs via genetic modification and directed evolution. mBio. 2022;13:e0038622. doi: 10.1128/mbio.00386-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00386-22</ArticleId><ArticleId IdType="pmc">PMC9239201</ArticleId><ArticleId IdType="pubmed">35481749</ArticleId></ArticleIdList></Reference><Reference><Citation>Waickman AT, Victor K, Li T, Hatch K, Rutvisuttinunt W, Medin C, Gabriel B, Jarman RG, Friberg H, Currier JR. Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling. Nature Communications. 2019;10:3666. doi: 10.1038/s41467-019-11634-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11634-7</ArticleId><ArticleId IdType="pmc">PMC6694189</ArticleId><ArticleId IdType="pubmed">31413301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A. Personal View Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In. Lancet Infect Dis. 2019;19:e31&#x2013;e38. doi: 10.1016/S1473-3099(18)30494-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30494-8</ArticleId><ArticleId IdType="pubmed">30195995</ArticleId></ArticleIdList></Reference><Reference><Citation>Young E, Carnahan RH, Andrade DV, Kose N, Nargi RS, Fritch EJ, Munt JE, Doyle MP, White L, Baric TJ, Stoops M, DeSilva A, Tse LV, Martinez DR, Zhu D, Metz S, Wong MP, Espinosa DA, Montoya M, Biering SB, Sukulpolvi-Petty S, Kuan G, Balmaseda A, Diamond MS, Harris E, Crowe JE, Baric RS. Identification of dengue virus serotype 3 specific antigenic sites targeted by neutralizing human antibodies. Cell Host &amp; Microbe. 2020;27:710&#x2013;724. doi: 10.1016/j.chom.2020.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.007</ArticleId><ArticleId IdType="pmc">PMC7309352</ArticleId><ArticleId IdType="pubmed">32407709</ArticleId></ArticleIdList></Reference><Reference><Citation>Young E, Yount B, Pantoja P, Henein S, Meganck RM, McBride J, Munt JE, Baric TJ, Zhu D, Scobey T, Dong S, Tse LV, Martinez MI, Burgos AG, Graham RL, White L, DeSilva A, Sariol CA, Baric RS. A live dengue virus vaccine carrying A chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. Nature Communications. 2023;14:36702. doi: 10.1038/s41467-023-36702-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36702-x</ArticleId><ArticleId IdType="pmc">PMC10009830</ArticleId><ArticleId IdType="pubmed">36914616</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Li L, Woodson SE, Huang CY-H, Kinney RM, Barrett ADT, Beasley DWC. A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus. Virology. 2006;353:35&#x2013;40. doi: 10.1016/j.virol.2006.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2006.05.025</ArticleId><ArticleId IdType="pubmed">16806383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>